RxDoctor Payments Data

Michael Shomaker, MD

Nephrology · Thornton, CONPI 1932276581

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,620 of the $40,828 with a category attached, or 92.1%. Boehringer Ingelheim accounts for 90.7% of it on its own, with 17 other manufacturers making up the rest. Among nephrology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,828in general payments, 2019–2025

Across 92 payments — averaging $443.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$37K
  • Lilly USA, LLC$2K
  • AstraZeneca$414
  • Nxstage Medical, Inc.$220
  • Otsuka America Pharmaceutical, Inc.$207
  • GSK$206
  • plus $703 from 12 others

What the payments were for

  • Speaking & faculty fees$37,62092%
  • Travel & lodging$9212%
  • Food & beverage$2,1615%
  • Education$1260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,828 in reported general payments places this provider in the 95th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$162,476
Medicare patients
234
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide15$100,230
LokelmaSodium Zirconium Cyclosilicate11$24,615
JardianceEmpagliflozin22$15,395
FarxigaDapagliflozin Propanediol16$14,776
Sevelamer Carbonate28$5,412
Calcitriol67$2,013
Labetalol Hcl55$1,727
Calcium Acetate12$1,370
Midodrine Hcl14$1,177
Furosemide65$508
Tamsulosin Hcl58$464
Hydralazine Hcl31$399
Amlodipine Besylate57$317
Lisinopril48$307
Allopurinol22$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$414$39,39127 claims
Boehringer IngelheimJardiance$37,017$15,39522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 nephrology providers in Colorado.

Other nephrology in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →